Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer
pharmafile | October 1, 2019 | News story | Manufacturing and Production, Research and Development | ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer
Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new data showing that its microtubule inhibitor Jevtana (cabazitaxel) met its primary endpoint in the treatment of metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone.
It was shown that the combo more than doubled radiographic progression free survival (rPFS) to a median of eight months, compared to 3.7 months with abiraterone or enzalutamide, clearing the primary endpoint of the study.
Jevtana also extended overall survival by a median of 13.6 months compared to 11 months and reduced any-cause risk of death by 36% compared to abiraterone or enzalutamide, meeting a key secondary endpoint of the trial. Progression-free survival was also improved by a median 4.4 months versus 2.7.
The findings related specifically to 255 mCRPC patients with a median age of 70 years who were previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent
“In this study, treatment with Jevtana significantly improved radiographic progression free survival and overall survival compared with enzalutamide or abiraterone,” said Professor Ronald de Wit from Erasmus MC University Hospital, Rotterdam, and the lead investigator of the CARD study. “These results are exciting as they have the potential to impact treatment guidelines for metastatic prostate cancer and current clinical practice.”
Matt Fellows
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
